GlassScriptPhysician profile
Sean P Davitt
NPI 1144222407
$2,528.57
in general payments reported to CMS, 2019-2025
24 companies · $930 in 2025
The $930 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $189 · 2021: $199 · 2022: $90.00 · 2023: $219 · 2024: $469 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $421.61 | 2022-2025 | Hydrus Microstent, Tryptyr, Eysuvis |
| Abbvie INC. | $272.86 | 2023-2025 | Durysta |
| Allergan, INC. | $232.86 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $209.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $189.63 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $141.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $126.81 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Harrow Eye, LLC | $97.32 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $84.29 | 2024 | Dextenza |
| Amgen INC. | $82.00 | 2024-2025 | Tepezza |
| Lensar, INC. | $74.60 | 2024 | Lensar Laser System |
| Thea Pharma INC. | $65.88 | 2024-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $64.25 | 2021-2025 | |
| Biotissue Holdings INC. | $45.97 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $45.44 | 2024-2025 | Xiidra, Miebo |
| Rayner Intraocular Lenses Limited | $42.14 | 2022-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Horizon Therapeutics Plc | $38.14 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.87 | 2019-2020 | |
| Halozyme INC | $35.05 | 2025 | Hylenex Recombinant |
| Glaukos Corporation | $32.45 | 2025 | Idosetr |
| Rxsight INC | $32.36 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Shire North American Group INC | $27.48 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Davitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.